ViceBio
Latest round
- Series B
Last raised
- Sep 2024
Total raised
- $100M
Investors
- 6
About ViceBio
ViceBio Limited is a biotechnology firm founded in 2019 with headquarters in London, UK. The company specializes in creating advanced vaccines for viral respiratory diseases.A.15 billion, plus an additional payment of up to USD 450 million based on development and regulatory achievements. The transaction is subject to customary closing conditions, including receipt of regulatory approvals. expected to close in Q4 2025. ViceBio specializes in the development of next-generation vaccines targeting viral respiratory diseases, utilizing their innovative Molecular Clamp technology. This technology allows the creation of vaccines that provide broad protection against multiple pathogens and offers ready-to-use formulations that facilitate seamless manufacturability. Key products are aimed at addressing global health challenges related to respiratory diseases such as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). ViceBio's customer base includes healthcare providers, governmental health organizations, and pharmaceutical companies primarily in Europe, North America, and Australia. The vaccines are designed for diverse end users, particularly vulnerable populations including infants, the elderly, and individuals with compromised immune systems. ViceBio generates revenue through strategic partnerships and collaborations with healthcare organizations and pharmaceutical companies. The revenue stream primarily consists of direct sales of innovative vaccine formulations structured as B2B agreements with health systems and distributors, enhanced by bulk purchasing contracts that facilitate access to their products for large healthcare providers. The revenue model benefits from ongoing clinical studies and advancements in their vaccine pipeline, setting the stage for future product launches and expanded market reach. Their products, especially those developed using the Molecular Clamp technology, are positioned to attract market interest upon release, which will contribute to the company’s financial performance.
Who invested in ViceBio
6 investors across 1 round
See all investors in ViceBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Sep 23, 2024
Amount
$100M
Investors
Questions about ViceBio
Who invested in ViceBio?
ViceBio has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ViceBio raised?
ViceBio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ViceBio last raise money?
ViceBio's most recent round on record is a Series B, in Sep 2024.
What does ViceBio do?
ViceBio Limited is a biotechnology firm founded in 2019 with headquarters in London, UK.
Where is ViceBio headquartered?
ViceBio is headquartered in London, UK.
Which VCs invest in companies like ViceBio?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at ViceBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like ViceBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.